 Mallinckrodt PLC said its full-year results are looking "promising" as the company posted a narrower fiscal third-quarter loss amid a surge in specialty pharmaceutical revenue. . The company boosted its full-year adjusted earnings guidance by 70 cents to $4 to $4.30, while raising its revenue outlook to $2.35 billion to $2.45 billion from the previous range of $2.28 billion to $2.38 billion. . "This...
  